- $122.83m
- $98.88m
- CNY650.71m
Brief: Genetron Health Reports Unaudited First Quarter 2022 Financial Results
U.S. STOCKS ON THE MOVE-Lithium stocks, 3M, TG Therapeutics
U.S. STOCKS ON THE MOVE-Salesforce, Enochian BioSciences, Spark Networks
Genetron rises on EU nod for multi-gene test
Brief: Genetron Health Receives CE Mark For FusionScan Plus Kit For Human Multi-Genes
Brief: Genetron Health Receives CE Mark For Human B Lymphocyte Minimal Residual Disease Detection Kit SEQ-MRD
Brief: Publication In Clinical And Translational Medicine Demonstrates Mutation Capsule's Potential In MRD Assay Developments
Brief: Genetron Health Posts Qtrly Loss Per Share $0.06
Brief: Genetron Health Reiterates Full Year 2021 Revenue Guidance
Brief: Genetron Holdings Reports Q3 Revenue Of RMB 152.5 Mln
Development Agreement With Astrazeneca R&D China For Personalized MRD Tests For Solid Tumors In China
Brief: Genetron Health Establishes Strategic Partnership With Neogenomics To Drive Global Oncology Drug Research And Development
Brief: Genetron Health And Fosun Pharma Announce Exclusive Partnership To Commercialize SEQ-MRD In China
U.S. RESEARCH ROUNDUP-Altice USA, Kinnate Biopharma, Omeros
Brief: Genetron Health And Impact Therapeutics Announce Partnership To Drive Development Of Synthetic Lethal Product Pipeline
U.S. RESEARCH ROUNDUP- Altice USA, Kinnate Biopharma, Omeros
Brief: Genetron Health Posts Q2 Loss Per Share $0.03
Ayvakit (Avapritinib) Companion Diagnostic Test Enters Priority Review And Approval Process In China
Genetron up on EU nod for lung cancer test, COVID-19 test data